Millennium Management’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.89M Buy
+642,448
New +$2.81M ﹤0.01% 3506
2025
Q4
Sell
-528,340
Closed -$2.4M 5950
2025
Q3
$2.4M Buy
528,340
+28,857
+6% +$106K ﹤0.01% 3870
2025
Q2
$1.54M Buy
499,483
+151,263
+43% +$502K ﹤0.01% 4097
2025
Q1
$1.22M Buy
348,220
+5,192
+2% +$17.3K ﹤0.01% 4210
2024
Q4
$1.12M Buy
343,028
+92,068
+37% +$339K ﹤0.01% 4108
2024
Q3
$966K Buy
250,960
+41,991
+20% +$161K ﹤0.01% 4309
2024
Q2
$646K Sell
208,969
-33,243
-14% -$99.7K ﹤0.01% 4430
2024
Q1
$625K Sell
242,212
-1,295,712
-84% -$3.36M ﹤0.01% 4661
2023
Q4
$3.84M Sell
1,537,924
-45,648
-3% -$89.4K ﹤0.01% 3015
2023
Q3
$3.21M Sell
1,583,572
-118,610
-7% -$249K ﹤0.01% 3134
2023
Q2
$3.92M Buy
1,702,182
+41,616
+3% +$108K ﹤0.01% 2887
2023
Q1
$5.03M Sell
1,660,566
-192,149
-10% -$542K ﹤0.01% 2600
2022
Q4
$4.32M Sell
1,852,715
-1,657,473
-47% -$3.97M ﹤0.01% 2939
2022
Q3
$6.7M Sell
3,510,188
-648,876
-16% -$1.53M ﹤0.01% 2608
2022
Q2
$11.3M Buy
4,159,064
+2,142,740
+106% +$5.48M 0.01% 1907
2022
Q1
$6.01M Sell
2,016,324
-1,022,861
-34% -$3.13M ﹤0.01% 2727
2021
Q4
$11.8M Buy
3,039,185
+2,017,490
+197% +$7.84M 0.01% 1968
2021
Q3
$4.38M Buy
+1,021,695
New +$3.4M ﹤0.01% 3013
2021
Q2
Sell
-523,263
Closed -$1.74M 6453
2021
Q1
$1.74M Buy
523,263
+342,301
+189% +$1.32M ﹤0.01% 3660
2020
Q4
$642K Buy
+180,962
New +$634K ﹤0.01% 4019
2020
Q3
Sell
-222,573
Closed -$405K 4384
2020
Q2
$405K Sell
222,573
-624,591
-74% -$1.02M ﹤0.01% 3529
2020
Q1
$856K Buy
847,164
+551,188
+186% +$1.49M ﹤0.01% 2563
2019
Q4
$823K Sell
295,976
-60,090
-17% -$97.2K ﹤0.01% 3091
2019
Q3
$543K Sell
356,066
-164,959
-32% -$284K ﹤0.01% 3203
2019
Q2
$1.08M Buy
+521,025
New +$1.33M ﹤0.01% 2757
2018
Q4
Sell
-30,924
Closed -$292K 3696
2018
Q3
$292K Sell
30,924
-56,165
-64% -$558K ﹤0.01% 3493
2018
Q2
$636K Buy
87,089
+73,882
+559% +$440K ﹤0.01% 3056
2018
Q1
$66K Sell
13,207
-68,800
-84% -$364K ﹤0.01% 3518
2017
Q4
$414K Buy
82,007
+61,961
+309% +$363K ﹤0.01% 3187
2017
Q3
$124K Buy
+20,046
New +$85.7K ﹤0.01% 3336
2017
Q2
Sell
-45,818
Closed -$149K 3404
2017
Q1
$149K Buy
45,818
+26,614
+139% +$73.8K ﹤0.01% 3279
2016
Q4
$47K Sell
19,204
-456,918
-96% -$1.33M ﹤0.01% 3257
2016
Q3
$1.64M Sell
476,122
-109,954
-19% -$430K ﹤0.01% 2036
2016
Q2
$2.04M Sell
586,076
-211,664
-27% -$896K ﹤0.01% 1770
2016
Q1
$3.29M Sell
797,740
-406,705
-34% -$1.45M 0.01% 1499
2015
Q4
$5.36M Sell
1,204,445
-151,394
-11% -$830K 0.01% 1313
2015
Q3
$8.26M Sell
1,355,839
-7,186
-0.5% -$63.7K 0.02% 1040
2015
Q2
$16.2M Buy
1,363,025
+988,268
+264% +$15M 0.03% 725
2015
Q1
$6.54M Buy
+374,757
New +$7.68M 0.01% 1271
2014
Q4
Sell
-12,600
Closed -$266K 3866
2014
Q3
$266K Sell
12,600
-130,226
-91% -$2.13M ﹤0.01% 3180
2014
Q2
$1.86M Buy
142,826
+123,267
+630% +$1.75M 0.01% 1826
2014
Q1
$420K Buy
+19,559
New +$351K ﹤0.01% 2726

Other funds holding ABUS

Millennium Management's ABUS Position: Q1 2026 in Review

Millennium Management opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 642,448 shares worth $2.89M. The stake represents ﹤0.01% of the portfolio and ranks #3506 among its holdings. This is a return to the name: Millennium Management previously reported a position in ABUS as recently as Q3 2025.

Millennium Management first reported a position in ABUS in Q1 2014 and has held it in 42 quarters since. The position peaked at $16.2M in Q2 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Millennium Management held 642,448 shares of Arbutus Biopharma worth $2.89M as of Q1 2026.
  • Arbutus Biopharma was a new Millennium Management position in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3506 holding.
  • Millennium Management first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 42 quarters since.
  • Millennium Management's Arbutus Biopharma position peaked at $16.2M in Q2 2015.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.